ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company’s logic-gate-based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio’s technologies are specifically designed to prevent antigen escape, prevent ‘on-target – off-tumor’ toxicities, and overcome the immunosuppressive tumor microenvironment. The company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from University of California, Los Angeles (UCLA), and Gideon Gross, Ph.D., from the MIGAL-Galilee Research Institute.
Location: United States, California, Camarillo
Employees: 51-200
Total raised: $111M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.01.2022 | Series B | $111M | Foresite C... |
Mentions in press and media 11
| Date | Title | Description | Source |
| 08.02.2023 | ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Dire... | Seasoned executive brings decades of experience in capital markets, finance, and corporate strategy ... | einpresswi... |
| 21.01.2022 | ImmPACT Bio Closes $111M Series B Financing | Sumant Ramachandra, MD, PhD, MBA, ImmPACT Bio president and CEO ImmPACT Bio, a Camarillo CA-based c... | finsmes.co... |
| 20.01.2022 | Novartis-backed ImmPACT Bio snags $111M and new CEO as cance... | Looking to make an impact on the cancer CAR-T cell therapy market, Novartis-backed ImmPACT Bio now h... | fiercebiot... |
| 20.01.2022 | ImmPACT Bio Lands $111M For Cancer Therapy | Camarillo-based ImmPACT Bio, a company developing cancer therapies, said this week that it has raise... | socaltech.... |
| 20.01.2022 | ImmPACT Bio Raises $111 Million to Advance Promising Cancer ... | When Sumant Ramachandra first stumbled upon oncology startup ImmPACT Bio, the Harvard Medical physic... | dot.la/imm... |
| 20.01.2022 | ImmPACT Bio Closes $111 Million Series B Financing, Names Ne... | - | jnjinnovat... |
| 20.01.2022 | Novartis-backed ImmPACT Bio snags $111M and new CEO as cance... | Looking to make an impact on the cancer CAR-T cell therapy market, Novartis-backed ImmPACT Bio now h... | fiercebiot... |
| 20.01.2022 | ImmPACT Bio Closes $111 Million Series B Financing, Names Ne... | CAMARILLO, Calif., Jan. 20, 2022 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a ... | marketscre... |
| 20.01.2022 | ImmPACT Bio Raises $111 Million to Advance Promising Cancer ... | When Sumant Ramachandra stumbled upon oncology startup ImmPACT Bio, the Harvard Medical physician-tu... | dot.la/imm... |
| 20.08.2020 | ImmPACT Bio Grabs $18M Series A Financing Round | CAMARILLO, CA, ImmPACT Bio has secured an $18 million equity financing round. >> Click here... | vcnewsdail... |
Show more